Navigation Links
OvaGene Oncology Joins The Gynecologic Oncology Group (GOG) Industry Collaboration Team to Advance Gynecologic Cancer Research
Date:8/4/2010

IRVINE, Calif., Aug. 4 /PRNewswire/ -- OvaGene Oncology Inc., a biotechnology company specializing in the development and commercialization of personalized DNA-based diagnostics for gynecologic cancer, is pleased to announce their partnership with The Gynecologic Oncology Group (GOG) through the Industry Collaboration Team (ICT) program.  By becoming a member of the ICT, OvaGene Oncology demonstrates its commitment to building a strong partnership with the GOG research groups, namely medical centers, universities, and pharmaceutical companies dedicated to advancing the scientific and clinical knowledge of gynecologic cancers.  

OvaGene's mission to improve the quality of life and survival for gynecologic cancer patients is further enhanced by joining this select group.  The Industry Collaboration Team has a limited membership and OvaGene is honored to have been given an opportunity to become a member. By joining the ICT program, OvaGene will gain direct access to oncology leaders and key decision makers in the field gynecologic oncology.  This will facilitate direct communication with the cancer treating physicians about OvaGene's products and diagnostic research capabilities. The valuable feedback provided can help accelerate the development of OvaGene's product pipeline by allowing the company to identify and address unmet clinical needs.

"We are very pleased to be an ICT member," said William Ricketts, Ph.D., Chief Scientific Officer for OvaGene.  "The GOG has one of the largest archived and annotated gynecologic tumor banks.  It is a privilege to be given the opportunity to collaborate with the GOG as a member of the ICT and potentially on studies focused to discover and validate new molecular diagnostics. This will help us bring clinically useful tests to market for improved patient care and outcome."  

Dr. Neil Finkler, M.D., Chief Medical Officer for OvaGene stated, "We are very enthusiastic about this collaboration. The ability to run our clinical studies on archived tissues from the GOG, as well as future prospective trials, adds an additional level of validation and scientific review to our studies that will ultimately improve the quality of our product offerings leading to improved patient care."

About OvaGene Oncology

OvaGene Oncology is a molecular diagnostics company, located in Orange County California, dedicated to improving cancer care and outcomes for gynecologic cancer patients through the development of novel gene-based assays.  The company plans to offer proprietary and non-proprietary molecular diagnostic assays to assist physicians in the prognosis of gynecologic cancers as well as therapy selection, including radiation and chemotherapy.  There are over 11,000 cases of cervical cancer, 25,000 cases of ovarian cancer and 42,000 cases of endometrial cancer diagnosed each year in the United States.  The total market for OvaGene's genomic assays is over 80,000 gynecologic cancer cases diagnosed annually. Please visit our website at www.ovagene.com for more information about our company.

About The Gynecologic Oncology Group

The Gynecologic Oncology Group ("GOG") is a national organization dedicated to clinical research in the field of gynecologic cancer. It is one of the cooperative clinical trial research groups funded by the National Cancer Institute (NCI). The purpose and mission of the GOG is to improve and expand the treatment of gynecologic cancer. These goals are met through an exchange of information on programs of study, teaching methods and research activities among gynecologic oncologists, medical oncologists, radiation oncologists, nurse oncologists, pathologists, and basic scientists.  Visit www.gog.org for more details.


'/>"/>
SOURCE OvaGene Oncology Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. OvaGene Oncology Opens New Innovative Gynecologic Cancer Laboratory and Research Facility
2. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
3. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
6. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
7. University of Pennsylvania School of Medicine Study Shows Significant Differences in English- and Spanish-speakers Use of Oncology Websites
8. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
9. Pharsight Uses FDA Disease Model to Support Oncology Drug Development
10. US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium
11. IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology ... outcomes platform, Bracket eCOA (SM) 6.0, at the 52 ... 30, 2016 in Philadelphia , Pennsylvania.  A ... product of its kind to fully integrate with RTSM, will ... 6.0 is a flexible platform for electronic clinical outcomes assessments ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... environments  Oticon , industry leaders in ... the launch of Oticon Opn ™, the world,s ... world of possibilities for IoT devices.      ... Opn, Oticon introduces a number of ,world firsts,: ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/27/2016)... ... 2016 , ... A revolution is underway. Brooklyn-based company, ... for the millions of people who require these medical transport services annually. ... the use of technology. Now, SmartEMS has put forth an industry-changing app that ...
(Date:6/26/2016)... ... 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment ... Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This ... of the world’s leading providers of cereal and other breakfast foods. Its residents often ...
(Date:6/26/2016)... ... ... blind and certified personal trainer is helping to develop a weight loss fitness plan that ... the two major problems leading the fitness industry today:, , All ... They don’t eliminate all the reasons people quit their exercise program , ...
(Date:6/25/2016)... ... 25, 2016 , ... Austin residents seeking Mohs surgery services, can now turn ... to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization ... selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction ...
Breaking Medicine News(10 mins):